Research Article

The Predictive Value of Growth Differentiation Factor-15 in Recurrence of Atrial Fibrillation after Catheter Ablation

Ying Wei, Shuwang Liu, Haiyi Yu, Yuan Zhang, Wei Gao, Ming Cui, and Lei Li

1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, China
2Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, China
3Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, China
4Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China

Correspondence should be addressed to Ming Cui; mingcui@bjmu.edu.cn and Lei Li; dr_lilei@bjmu.edu.cn

Received 21 June 2020; Revised 13 July 2020; Accepted 15 July 2020; Published 21 August 2020

1. Introduction

As the most common sustained arrhythmia, atrial fibrillation (AF) represents an evolving, global epidemic problem and a major public health challenge worldwide [1]. With the aging of population intensifies, the morbidity of AF is increasing. The prevalence of AF in the developed world is 1% to 2% in the general population [2, 3] and increases to 8-15% at 80 years of age or older [4, 5]. AF remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. The increasing prevalence of AF bears a heavy public health burden.

In the past decade, although advanced ablation techniques dramatically improved the outcomes [2, 6, 7], AF recurrence is still common and a significant number of patients continue to suffer complications [8], such as cardiac tamponade, pulmonary vein (PV) stenosis, and vascular injuries. It is reported that the recurrence rates after ablation were 20–50% [9]. The efficacy of ablation is considered quite challenging due to many factors, including the type of AF,
Ablative techniques, operator experience, clinical parameters, and strategy of follow-up [10]. However, a reliable parameter for predicting recurrent events of AF after ablation is absent.

GDF-15 was described as a divergent member of the human transforming growth factor β (TGF-β) superfamily. Its expression would increase in response to diverse cellular stress signals, such as inflammation, hypoxia/anoxia, acute tissue injuries, and the tumor process [11]. Cardiovascular disease is also a major driver of GDF-15 production [12]. Our group has demonstrated in vivo that GDF-15 could enhance the proliferation of fibroblasts and may participate in the progression of myocardial fibrosis [13]. Research in the past showed that GDF-15 played an active role in left ventricular remodeling [14]. Moreover, GDF-15 in serum was higher in patients with atrial fibrillation [15–17], and it could be used as a prognostic indicator for bleeding and death [18]. It is recognized that human transforming growth factor β1 (TGF-β1), which is also a member of the TGF-β family, exhibited a profibrotic effect on cardiomyocytes and thus increased the chances to develop AF [19]. The animal model showed that it could be used as a therapy target against fibrosis [20]. Since in AF patients, levels of TGF-β1 and GDF-15 in serum and atrial tissue both elevate [15–17, 21, 22], and they are both members of the TGF-β family, we infer that GDF-15 also have an important role in atrial fibrosis. However, few studies had focused on how GDF-15 correlates with atrial structural remodeling and AF types in AF patients. And there has been no research concerning the relationship between GDF-15 and AF recurrences up until now. In this study, we planned to explore whether the serum GDF-15 level measured preprocedure could predict AF recurrent events in AF patients after RFCA.

2. Methods

2.1. Patient Enrollment. Our study was a prospective, single-center study. From October 2017 to October 2019, a total of 150 consecutive AF patients admitted to Peking University Third Hospital for their initial circumferential pulmonary vein isolation (CPVI) based catheter ablation were qualified and recruited according to our criteria.

The exclusion criteria included acute coronary syndromes, congenital heart disease, valvular heart disease of any degree, severe heart failure (NYHA III class), severe liver disorders [aspartate aminotransferase (AST) > 40 U/L or alanine aminotransferase (ALT) > 40 U/L] or kidney disorders [creatinine > 4.0 mg/dl], current infection, hematological disease, and thyroid-related hospital diagnoses. The study was approved by the Ethics Review Boards of Peking University Third Hospital (Approval number: 077-02, Beijing, China). Written informed consent was obtained from all participants.

2.2. Clinical Data and Measurement

2.2.1. Collection of Clinical Information. The demographic and clinical information of all patients were collected, including age, gender, body mass index (BMI), heart rate, previous history, and the use of medications. CHA2DS2-VASc and HAS-BLED scores for stroke and bleeding risk were also calculated.

2.2.2. Measurement of Blood Parameters. Complete blood count, fasting blood glucose (FBG), hemoglobin Alc (HBA1c), creatinine (Cr), high-sensitivity C-reaction protein (hs-CRP), N-Terminal pro-brain natriuretic peptide (NT-proBNP), blood urea nitrogen (BUN), and uric acid (UA) were measured by clinical laboratories in Peking University Third Hospital using the standard laboratory procedures. The estimated glomerular filtration rate (eGFR) was obtained by the Simplified MDRD formula: GFR (ml/min · 1.73m2) = 186 × [Scr(mg/dl)] − 1.154 × age (years) − 0.203 [×0.742 for female, ×1.233 for Chinese].

2.2.3. Measurement of GDF-15. Venous blood samples were obtained following overnight fasting (8 hours), after a 30-minute rest in the sitting position. Samples were taken from the cubital vein into blood tubes and immediately stored on ice at 4°C. Serum samples were processed within 30 minutes after collection by centrifugation at 3000 g for 15 minutes at 4°C. To avoid repeated freeze-and-thaw cycles, each serum sample was divided into 0.2 mL aliquots and frozen immediately at -80°C. Serum GDF-15 level was determined using a commercially available sandwich ELISA kit (R&D Company, USA). The samples were analyzed using the instructed procedures.

2.2.4. Echocardiography. Transesophageal echocardiography (TEE) using GE Vivid E9 equipped with a multiplane TEE probe was performed within 24 hours before RFCA. Left atrial appendage images were obtained both in the basal short-axis view with a transverse scan and in the left ventricle-left atrial 2-chamber view with a vertical scan [23]. The flow velocity in and out of left atrial appendage was obtained by pulsed-wave Doppler interrogation at the left atrial appendage ostium and was measured as the average value of 10 consecutive fibrillatory emptying waves [24]. All TEE images were stored for offline analysis (QLAB cardiac 3DQ, Philips Medical Systems).

Two-dimensional transthoracic echocardiography was performed before the TEE study, using GE Vivid E9 and a 3.5 MHz transducer. Standard views including M-mode, 2D images, and Doppler and color-Doppler data were acquired from the parasternal and apical views (4-, 2-, and 3-chamber view), and parameters were recorded [24, 25].

2.3. Electrophysiological Study. Multidetector computed tomography (MDCT) scanning of the left atrial (LA) and pulmonary veins was performed to guide the ablation procedure by a 64-slice scanner (SOMATOM Definition Flash, Siemens, Munich, Germany).

All participants under intravenous sedation underwent the CPVI based ablation procedure guided by 3-D mapping in the CARTO 3 system [7, 26]. The technique of CPVI was described briefly as follows. Firstly, two transseptal punctures were performed to explore LA, followed by 5,000 IU of unfractionated heparin administration. The geometry of LA and PV trunk was reconstructed with a PentaRay Catheter
Mediators of Inflammation

(Biosense Webster, USA) in the CARTO 3 system compared with MDCT.

An irrigated radiofrequency ablation was performed along each PV antrum in a point-by-point fashion for encircling PVs. Smart Touch force-sensing catheter (Biosense Webster, USA) was used during the procedure. Radiofrequency energy was applied at 25–40 W with a temperature of 43°C and an irrigation flow of 8–25 mL/min until a bipolar voltage of <0.1 mV was achieved, with a maximum of 60 seconds per point. Endpoints of the procedure were completeness of PV isolation from LA. Successful PV isolation was defined as the elimination (or dissociation) of all the PV potentials recorded from a PentaRay Catheter. Ablation of LA roofline and other nonpulmonary vein foci triggering AF were added according to electrophysiological mapping results. All block lines were confirmed by the electrophysiological study. If AF continued after the ablation, biphasic direct current shocks with the energy of 100–150 J were administered to restore sinus rhythm, or ibutilide was given intravenously. Heparin was repeated during the procedure. Activated clotting time (ACT) of whole blood, the target value of which was 200–350 s, was tested regularly to adjust the dosage of heparin every 30–60 minutes.

2.4. Follow-Up and AF Recurrence Assessment. Amiodarone was administered to the patients without contraindications for 3 months after the procedure. If there was no atrial tachyarrhythmia, an attempt was made in all patients to cease amiodarone and any other antiarrhythmic drugs (AADs). Vitamin K antagonist or dabigatran etexilate or rivaroxaban were prescribed for a minimum of 3 months without contraindications and potentially discontinued in the cases of a low thromboembolic score (CHA2DS2-VASc score 0 or 1).

All participants had regular follow-up visits with clinical evaluation. They received face-to-face interviews at the outpatient clinic every 3 months in the first year, and every 6 months afterwards. Blood samples of the patients were collected three months after catheter ablation. The total follow-up period was 2 years. 12-lead ECG and 72-hour Holter were performed at 1st, 3rd, 6th, 12th, 18th, and 24th months after the procedure. Every symptomatic patient was referred to a new ECG. The endpoint of the study is recurrent AF. Recurrence of AF postablation is defined as a recurrence of AF/atrial flutter/atrial tachyarrhythmia of at least 30 s duration that is documented by an ECG or device recording system after a blanking period of 3 months [9]. Two electrophysiologists performed the clinical follow-up and data collection independently.

2.5. Statistical Analysis. The Kolmogorov-Smirnov test was used to test normality and a P value > 0.05 was defined as normally distributed data. Data were expressed as the mean value ± standard deviation (X ± SD) in continuous variables of a normal distribution, median ± quartile ranges (QR) in abnormal distribution and percentage, or proportion in categorical variables as appropriate. Continuous variables that showed normal distribution were compared using the Student’s t-test, whereas the Mann-Whitney U test was used for nonnormally distributed samples, and chi-square tests for categorical data. Wilcoxon matched-pairs signed-rank test was used to compare the GDF-15 levels at baseline and three months after RFCA. Receiver operating characteristic (ROC) analysis was made to determine the cut-off value of GDF-15 to predict AF recurrence. A Kaplan-Meier curve censored for the recurrent event with a log-rank test served for the cumulative recurrence rate after ablation. Estimations of recurrence risks were performed using the Cox proportional hazard models by univariate and multivariate analysis. Spearman’s correlations were used to examine the relationship between GDF-15 and other variables. Results were expressed as the P value and hazard ratio (HR) in confidence interval (CI) of 95%.

All statistical analyses were computed in a commercially available statistical calculation program (SPSS 23.0, SPSS Inc., Chicago, Illinois). Figures were analyzed using GraphPad Prism (GraphPad Software Inc., San Diego, California). Statistical significance was defined as a two-sided P value < 0.05 for all comparisons.

3. Results

3.1. Baseline Characteristics. A total of 150 patients undergoing their initial ablation [85 men and 65 women, mean age (64 ± 11) years old] were analyzed.

After a median follow-up time of 14.0 months, 37 (24.7%) patients experienced recurrent events confirmed by atrial tachyarrhythmia or medical records, and 113 patients (75.3%) had maintained stable sinus rhythm.

Patients were divided into 2 groups according to whether AF recurred. Baseline characteristics are summarized in Table 1. It was found that the recurrence group was older, had higher rates of persistent AF, higher CHA2DS2-VASc and HAS-BLED scores and a lower proportion of NOAC usage (P < 0.05). As for laboratory results, AF recurrence group had a significantly higher level of NT-proBNP, and a significantly lower level of eGFR (P < 0.05). Regarding echocardiographic data, LAD, LAA, LAP, and RAA were significantly higher in the recurrence group. LAAV and LVEF were significantly lower in the recurrence group. Regarding electrophysiological study data, the recurrence group has a higher percentage of CPVI-only patients. Other baseline characteristics were similar between the 2 groups (P > 0.05).

3.2. Serum GDF-15 Level in AF Patients. Baseline serum GDF-15 level in the persistent AF group was significantly higher than the paroxysmal AF group [1140 (854–1701) ng/L vs. 1062 (651–1374) ng/L, P = 0.039]. Baseline serum GDF-15 level in the recurrence group was significantly higher than the non-recurrence group [1287 (889–1768) ng/L vs. 1062 (694–1373) ng/L, P = 0.022]. Blood samples of 95 (63.3%) patients were collected three months after RFCA. Serum GDF-15 level at three months after RFCA was significantly lower than the baseline [870 (579–1270) ng/L vs. 1155 (735–1632) ng/L, P < 0.001].

3.3. Predictive Value of Baseline GDF-15 for AF Recurrence. The cut-off value of GDF-15 obtained by ROC curve analysis was 1287.3 ng/L for prediction of AF recurrence (sensitivity: ...
Table 1: Baseline characteristics of patients with and without AF recurrence.

| Characteristics                  | Recurrence (n = 37) | No recurrence (n = 113) | P value |
|----------------------------------|---------------------|-------------------------|---------|
| **Clinical characters**          |                     |                         |         |
| Age (years)                      | 69 ± 9              | 63 ± 11                 | 0.005*  |
| Male, n (%)                      | 18 (48.6)           | 67 (59.3)               | 0.257   |
| BMI (kg/m²)                      | 26 ± 4              | 26 ± 4                  | 0.489   |
| Heart rate (bpm)                 | 80 ± 16             | 82 ± 16                 | 0.457   |
| AF duration (months)             | 24 (5–84)           | 13 (3–57)               | 0.152   |
| Persistent AF, n (%)             | 23 (62.2)           | 39 (34.5)               | 0.003*  |
| Stroke, n (%)                    | 15 (40.5)           | 30 (26.5)               | 0.107   |
| Hypertension, n (%)              | 26 (70.3)           | 68 (60.2)               | 0.271   |
| Hyperlipemia, n (%)              | 15 (40.5)           | 39 (34.5)               | 0.507   |
| Diabetes mellitus, n (%)         | 13 (35.1)           | 22 (19.5)               | 0.051   |
| CHD, n (%)                       | 8 (21.6)            | 11 (9.7)                | 0.059   |
| Smoker, n (%)                    | 6 (16.2)            | 13 (11.5)               | 0.643   |
| CHF, n (%)                       | 5 (13.5)            | 5 (4.4)                 | 0.123   |
| CHA2DS2-VASc score               | 3 (2–4.5)           | 2 (1–3)                 | 0.004*  |
| HASBLED score                    | 1 (1–2)             | 1 (0–1)                 | 0.016*  |
| **Medications**                  |                     |                         |         |
| NOAC, n (%)                      | 26 (70.3)           | 107 (94.7)              | <0.001* |
| Amiodarone, n (%)                | 26 (70.3)           | 91 (80.5)               | 0.191   |
| β-Blockers, n (%)                | 15 (40.5)           | 51 (45.1)               | 0.625   |
| ACEI/ARB, n (%)                  | 15 (40.5)           | 46 (40.7)               | 0.986   |
| CCB, n (%)                       | 17 (45.9)           | 35 (31.0)               | 0.097   |
| **Laboratory results**           |                     |                         |         |
| WBC (×10⁹/L)                     | 6.2 ± 1.6           | 6.0 ± 1.6               | 0.414   |
| FBG (mmol/L)                     | 5.7 (5.1–6.4)       | 5.3 (4.8–6.0)           | 0.075   |
| HbAlc (%)                        | 6.1 (5.8–6.6)       | 6.0 (5.7–6.4)           | 0.341   |
| Cr (mg/dl)                       | 0.90 ± 0.16         | 0.90 ± 0.17             | 0.866   |
| hs-CRP (mg/L)                    | 1.09 (0.44–3.09)    | 0.96 (0.38–2.94)        | 0.514   |
| NT-proBNP (pg/ml)                | 885.0 (228.3–1628.0)| 248.0 (94.3–604.9)      | <0.001* |
| BUN (mmol/L)                     | 5.7 ± 1.4           | 5.7 ± 1.7               | 0.829   |
| eGFR (ml/min)                    | 74 ± 11             | 81 ± 13                 | 0.010*  |
| UA (umol/L)                      | 345 (295–448)       | 346 (286–402)           | 0.707   |
| **Echocardiographic data**       |                     |                         |         |
| LAD (mm)                         | 41 ± 4              | 38 ± 4                  | <0.001* |
| LAA (cm²)                        | 26 ± 7              | 22 ± 4                  | 0.005*  |
| LVEDD (mm)                       | 48 ± 4              | 47 ± 4                  | 0.752   |
| LAP (mmHg)                       | 11 (9–14)           | 10 (9–11)               | 0.049*  |
| LVEF (%)                         | 68 (64–71)          | 70 (67–73)              | 0.036*  |
| RAA (cm²)                        | 20 (16–23)          | 16 (15–19)              | <0.001* |
| RVD (mm)                         | 21.2 (20.0–23.7)    | 21.0 (19.2–22.5)        | 0.428   |
| LAAV (m/s)                       | 0.35 (0.28–0.46)    | 0.50 (0.30–0.65)        | 0.004*  |
| **Electrophysiological study data** |                 |                         |         |
| Ablation time (s)                | 2298 (1846–2887)    | 2248 (1945–2971)        | 0.619   |
| Heparin dosage (IU)              | 7000 (7000–8000)    | 7000 (7000–7000)        | 0.386   |
| CPVI-only, n (%)                 | 14 (37.8)           | 72 (63.7)               | 0.006*  |

AF: atrial fibrillation; BMI: body mass index; CHD: coronary heart disease; CHF: chronic heart failure; NOAC: new oral anticoagulants; ACEI: angiotensin-converting enzyme inhibitors;ARB: angiotensin receptor blocker; CCB: calcium channel blocker; WBC: white blood cell; FBG: fasting blood glucose; HbAlc: hemoglobin A1c; Cr: creatinine; hs-CRP: high-sensitivity C-reaction protein; NT-proBNP: N-Terminal pro-brain natriuretic peptide; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; UA: uric acid; LAD: left atrial diameter; LAA: left atrial area; LVEDD: left ventricular end-diastolic dimension; LAP: left atrial pressure; LVEF: left ventricular ejection fraction; RAA: right atrial area; RVD: right ventricular diameter; LAAV: left atrial appendage flow velocity; CPVI: circumferential pulmonary vein isolation. *P < 0.05.
51.4%, specificity: 70.8%). The area under the curve (AUC) was 0.625 (95% CI 0.519-0.731, \( P = 0.022 \), Figure 1). All 150 AF patients were divided into two subgroups based on the baseline GDF-15 cut-off value (1287.3 ng/L). Kaplan-Meier analysis (Log Rank method) showed a significantly lower event-free survival time in the high GDF-15 group than the low GDF-15 group (17.1 months vs. 20.4 months, Log Rank \( P = 0.017 \), Figure 2).

3.4. Univariate and Multivariate Analyses of AF Recurrence after RFCA. Univariate and multivariate analysis results for AF recurrence are shown in Table 2. The variables significantly associated with AF recurrence included age, persistent AF, diabetes mellitus, NT-proBNP, LAD, LAAV, ablative strategy (CPVI-only), and baseline GDF-15. In the multivariate Cox regression, forward stepwise analysis adjusted by age, persistent AF, diabetes mellitus, NT-proBNP, eGFR, LAD, LAAV, ablative strategy (CPVI-only), and baseline GDF-15 indicated that baseline GDF-15 (HR 1.053, 95% CI 1.007-1.100, \( P = 0.022 \)) and LAD (HR 1.124, 95% CI 1.011-1.250, \( P = 0.030 \)) were both independent predictors of AF recurrence after RFCA.

3.5. The Correlation between Baseline GDF-15 and Other Characteristics. Among the clinical characters, laboratory results, and echocardiographic data, Spearman rank correlation analysis showed that the baseline serum GDF-15 level was positively correlated with age (\( r = 0.485, P < 0.001 \)), CHA\(_2\)DS\(_2\)-VASc score (\( r = 0.349, P < 0.001 \)), HASBLED score (\( r = 0.295, P < 0.001 \)), NT-proBNP (\( r = 0.232, P = 0.005 \)), LAP (\( r = 0.296, P < 0.001 \)), and also negatively correlated with eGFR (\( r = -0.332, P < 0.001 \)), LAAV (\( r = -0.235, P = 0.003 \)) (Table 3). However, there was no correlation between GDF-15 and other variables (\( P < 0.05 \)).

4. Discussion

This prospective study investigated the association between preprocedural serum GDF-15 level and recurrent events in 150 patients with AF after their initial catheter ablation. Our results showed that patients with higher baseline GDF-15 level were at greater risk and prone to suffer recurrent events. To the best of our knowledge, this is the first study investigating the role of GDF-15 to predict AF recurrence after catheter ablation.

Common mechanisms of atrial fibrillation include reentry, pulmonary vein trigger, abnormal autonomic nerve modulation, inflammation, and atrial remodeling. There are still recurrences of AF in some patients after catheter ablation, which mainly targets correcting atrial electrical remodeling. This indicates that correcting atrial electrical remodeling is not the only therapy target for AF. It has become popular to study the role and mechanism of atrial structural remodeling in the occurrence and development of AF. Atrial fibrosis is a key element of atrial structural remodeling. Fibrosis causes an increase in the volume of the dysfunctional extracellular matrix and is associated with cellular alterations such as hypertrophy, apoptosis, and membrane dysfunction within the atrial myocardium; in turn, these cause pathological alterations to atrial conduction, such as increased anisotropy, conduction block, and reentry, which can lead to AF [27]. LA enlargement and dysfunction are common in patients with AF and are always used to evaluate the severity degree of atrial structural remodeling [28]. Previous studies have shown that patients with larger LAD tend to have more chances to develop AF [29–32]. Also, AF patients with larger LAD or smaller LAAV, LVEF are at a greater risk of suffering from recurrence events [33–35]. Our study has also found that LAD and LAP were significantly higher in the patients with AF recurrence, and LAAV was significantly lower in the patients with AF recurrence. LAD was an independent predictor of AF recurrence after catheter ablation in the Cox model. Studies revealed that LAD, LAP, and LAAV are all important indicators of LA remodeling. In conclusion, our study suggested that the AF recurrence group had a severer degree of atrial structural remodeling.

We further found that in the persistent AF group and recurrence group, the serum GDF-15 level also increased accordingly. Cox model suggested that GDF-15 was an independent predictor of AF recurrence after RFCA. GDF-15 was a member of the human transforming growth factor \( \beta \) (TGF-\( \beta \)) superfamily. It was identified to have protective effects on inhibiting the proliferation and differentiation of cells, reducing ischemia-reperfusion injury and antiapoptosis [36, 37]. Our previous study showed that GDF-15 could enhance the proliferation of fibroblasts and may participate in the progression of myocardial fibrosis [13], and GDF-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation [38]. Atrial structural remodeling is closely related to atrial fibrosis and extracellular matrix. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are essential for the cardiac extracellular matrix.
remodeling. Nair and Gongora [39] reported that the plasma GDF-15 level was positively correlated with MMP, TIMPs. Zhou et al. [40] showed that the GDF-15 level in plasma and the GDF-15 mRNA level in atrial tissue of AF were both higher than those of participants with sinus rhythm, and the expression of GDF-15 was found to be positively related to the degree of cardiac fibrosis. Also, there exist longstanding electric stimulation, oxidative stress, and inflammatory response in the atrium of persistent AF patients. All these reactions could aggravate atrial structural remodeling and may result in an increased serum level of GDF-15. The above results indicated that GDF-15 might play an important role in atrial structural remodeling by collagen synthesis and transformation, thus participating in AF recurrence and the evolvement from paroxysmal AF to persistent AF. More importantly, we further found that the expression of GDF-15 level decreases after RFCA. As catheter ablation is one of the most effective ways to stop AF by PV isolation and correcting atrial electrical remodeling, AF burden decreases after RFCA, which could slow down the progression of atrial fibrosis. We infer this may have some association with a decreased level of GDF-15 after RFCA.

Our study has also found that the baseline serum GDF-15 level was positively correlated with LAP and negatively correlated with LAAV. After AF recurrence, the left atrium has changes in tissue, cells, electrical remodeling and hemodynamics, resulting in LAP progressively heightened. The elevation of LAP also shortens the effective refractory period of cardiomyocytes and increases the chances of developing AF [41]. When left ventricular diastolic dysfunction happens,
The expression of GDF-15 would increase in response to inflammation. Meanwhile, the relationship between WBC, hs-CRP with GDF-15 has not been reported before. We need to enroll more participants to further explore the association.

5. Limitations

This was a single-center study with its inherent limitations. Firstly, the sample size was relatively small which may cause a statistical bias. Our results need to be confirmed in future large multicenter prospective trials. Secondly, for paroxysmal AF patients, the rhythm may be different at the time of blood collection, which could make an effect on GDF-15 expression. Thirdly, the relationship between GDF-15 and echocardiographic data could not definitely prove that GDF-15 participates in the atrial structural remodeling process, which needs to be tested by some animal models and cell molecular biological experiments. Therefore, future studies are required to further evaluate the potential mechanism of GDF-15 in AF patients after catheter ablation.

6. Conclusions

Firstly, we found that serum GDF-15 level had positive correlations with LAP and negative correlations with LAAV, which suggested that GDF-15 may have clinical correlations with the atrial structural remodeling in AF patients. Moreover, our study found that the expression of GDF-15 in serum elevated in the persistent AF group compared with the paroxysmal AF group, also elevated in the recurrence group compared with the non-recurrence group, and decreased after RFCA. GDF-15 was an independent predictor for AF recurrence. This suggests that GDF-15 might be involved in the development of AF and become a new biomarker to predict AF recurrence after catheter ablation.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

The present study was performed by all authors. Lei Li and Ming Cui contributed to the conception, design, and supervision of the study. Ying Wei collected clinical information and blood samples from the patients, conducted ELISA experiments, and performed data analysis. Shuwang Liu and Yuan Zhang performed the clinical follow-up. Haiyi Yu and Wei Gao provided valuable reagents and helpful advice. Wei Gao and Lei Li contributed to the funding acquisition. Ying Wei and Lei Li wrote the manuscript. All authors discussed the results and contributed to the approval of the manuscript.
Acknowledgments

We would like to thank all the staff and participants for their contribution to the study. This work was supported by the Beijing Natural Science Foundation (grant No. 7182176 to Wei Gao) and the National Natural Science Foundation of China (grant No. 31700674 to Lei Li).

References

[1] C. T. January, L. S. Wann, J. S. Alpert et al., “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society,” Circulation, vol. 130, no. 23, pp. e199–e267, 2014.

[2] Authors/Task Force Members, A. J. Camm, G. Y. H. Lip et al., “2012 focused update of the ESC guidelines for the management of atrial fibrillation,” European Heart Journal, vol. 33, no. 21, pp. 2719–2747, 2012.

[3] J. Andrade, P. Khairy, D. Dobrev, and S. Nattel, “The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms,” Circulation Research, vol. 114, no. 9, pp. 1453–1468, 2014.

[4] V. Fuster, L. E. Ryden, D. S. Cannon et al., “2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Journal of the American College of Cardiology, vol. 57, no. 11, pp. e101–e198, 2011.

[5] T. Wilke, A. Groth, S. Mueller et al., “Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients,” Europace, vol. 15, no. 4, pp. 486–493, 2013.

[6] C. T. January, L. S. Wann, J. S. Alpert et al., “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society,” Circulation, vol. 130, no. 23, pp. 2071–2104, 2014.

[7] K. Nishida, T. Datino, L. Macle, and S. Nattel, “Atrial fibrillation ablation: translating basic mechanic insights to the patient,” Journal of the American College of Cardiology, vol. 64, no. 8, pp. 823–831, 2014.

[8] R. R. Tilz, A. Rillig, A. M. Thum et al., “Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy,” Journal of the American College of Cardiology, vol. 60, no. 19, pp. 1921–1929, 2012.

[9] H. Calkins, K. H. Kuck, R. Cappato et al., “2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design,” Journal of Interventional Cardiac Electrophysiology, vol. 33, no. 2, pp. 171–257, 2012.

[10] J. Cosedis Nielsen, A. Johannessen, P. Raatikainen et al., “Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation,” The New England journal of medicine., vol. 367, no. 17, pp. 1587–1595, 2012.

[11] J. Corre, B. Hebraud, and P. Bourin, “Concise review: growth differentiation factor 15 in pathology: a clinical role?” Stem Cells Translational Medicine, vol. 2, no. 12, pp. 946–952, 2013.

[12] K. C. Wollert, T. Kempf, and L. Wallentin, “Growth differentiation factor 15 as a biomarker in cardiovascular disease,” Clinical Chemistry, vol. 63, no. 1, pp. 140–151, 2017.

[13] Y. P. Wang, H. Y. Yu, M. Xu, and W. Gao, “Expression and significance of growth differentiation factor-15 in myocardial fibroblast,” Chinese Journal of Medicinal Guide, vol. 12, no. 4, pp. 633–635, 2010.

[14] J. Heger, E. Schiegnitz, D. von Waldhaussen, M. M. Anwar, H. M. Piper, and G. Euler, “Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes,” Journal of Cellular Physiology, vol. 224, no. 1, pp. 120–126, 2010.

[15] C. Bening, E.-A. Mazalu, J. Yaqub et al., “Atrial contractility and fibrotic biomarkers are associated with atrial fibrillation after elective coronary artery bypass grafting,” The Journal of Thoracic and Cardiovascular Surgery, vol. 159, no. 2, pp. 515–523, 2020.

[16] I. P. Doulamis, G. Samanidis, A. Tzani et al., “Proteomic profile of patients with atrial fibrillation undergoing cardiac surgery,” Interactive CardioVascular and Thoracic Surgery, vol. 28, no. 1, pp. 94–101, 2019.

[17] Q. Shao, H. Liu, C. Y. Ng et al., “Circulating serum levels of growth differentiation factor-15 and neuregulin-1 in patients with paroxysmal non-valvular atrial fibrillation,” International Journal of Cardiology, vol. 172, no. 2, pp. e311–e313, 2014.

[18] L. Wallentin, Z. Hijazi, U. Andersson et al., “Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation,” Circulation, vol. 130, no. 21, pp. 1847–1858, 2014.

[19] S. Verheule, T. Sato, T. Everett IV et al., “Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1,” Circulation Research, vol. 94, no. 11, pp. 1458–1465, 2004.

[20] M. Shimano, Y. Tsuji, Y. Inden et al., “Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure,” Heart Rhythm, vol. 5, no. 3, pp. 451–459, 2008.

[21] H. Xiao, H. Lei, S. Qin, K. Ma, and X. Wang, “TGF-beta1 expression and atrial myocardium fibrosis increase in atrial fibrillation secondary to rheumatic heart disease,” Clinical Cardiology, vol. 33, no. 3, pp. 149–156, 2010.

[22] F. Gramley, J. Lorenzen, E. Koellensperger, K. Kettering, C. Weiss, and T. Munzel, “Atrial fibrosis and atrial fibrillation: the role of the TGF-β1 signaling pathway,” International Journal of Cardiology, vol. 143, no. 3, pp. 405–413, 2010.

[23] F. A. Flachskampf, L. Badano, W. G. Daniel et al., “Recommendations for transoesophageal echocardiography: update 2010,” European Journal of Echocardiography, vol. 11, no. 7, pp. 557–576, 2010.

[24] M. H. Picard, D. Adams, S. M. Bierig et al., “American Society of Echocardiography recommendations for quality echocardiography laboratory operations,” Journal of the American Society of Echocardiography, vol. 24, no. 1, pp. 1–10, 2011.

[25] A. C. Y. To, S. D. Flamm, T. H. Marwick, and A. L. Klein, “Clinical utility of multimodality LA imaging: assessment of
Mediators of Inflammation

size, function, and structure,” JACC Cardiovascular imaging, vol. 4, no. 7, pp. 788–798, 2011.

[26] R. Latchamsetty and F. Morady, ”Catheter ablation of atrial fibrillation,” Cardiology Clinics, vol. 32, no. 4, pp. 551–561, 2014.

[27] G. A. Begg, A. V. Holden, G. Y. H. Lip, S. Plein, and M. H. Tayebjee, ”Assessment of atrial fibrosis for the rhythm control of atrial fibrillation,” International Journal of Cardiology, vol. 220, pp. 155–161, 2016.

[28] Y. Akutsu, K. Tanno, and Y. Kobayashi, ”The role of atrial structural Remodeling in atrial fibrillation ablation: an imaging point of view for predicting recurrence,” Journal of Atrial Fibrillation, vol. 5, no. 2, pp. 509–509, 2012.

[29] R. A. Winkle, J. W. E. Jarman, R. H. Mead et al., ”Predicting atrial fibrillation ablation outcome: the CAAP-AF score,” Heart Rhythm, vol. 13, no. 11, pp. 2119–2125, 2016.

[30] R. A. Winkle, R. H. Mead, G. Engel, and R. A. Patrawala, ”Long-term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation,” American Heart Journal, vol. 162, no. 1, pp. 193–200, 2011.

[31] J. W. McCready, T. Smedley, P. D. Lambiase et al., ”Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation,” Europace, vol. 13, no. 3, pp. 355–361, 2011.

[32] P. Leong-Sit, E. Zado, D. J. Callans et al., ”Efficacy and risk of atrial fibrillation ablation before 45 years of age,” Circulation. Arrhythmia and Electrophysiology, vol. 3, no. 5, pp. 452–457, 2010.

[33] Y. He, B. Zhang, F. Zhu, Z. Hu, J. Zhong, and W. Zhu, ”Trans-esophageal echocardiography measures left atrial appendage volume and function and predicts recurrence of paroxysmal atrial fibrillation after radiofrequency catheter ablation,” Echo-cardiography, vol. 35, no. 7, pp. 985–990, 2018.

[34] T. Kanda, M. Masuda, A. Sunaga et al., ”Low left atrial appendage flow velocity predicts recurrence of atrial fibrillation after catheter ablation of persistent atrial fibrillation,” Journal of Cardiology, vol. 66, no. 5, pp. 377–381, 2015.

[35] M. Linhart, T. Lewalter, E. L. Mittmann-Braun et al., ”Left atrial pressure as predictor for recurrence of atrial fibrillation after pulmonary vein isolation,” Journal of Interventional Cardiac Electrophysiology, vol. 38, no. 2, pp. 107–114, 2013.

[36] T. Kempf, M. Eden, J. Strelau et al., ”The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury,” Circulation Research, vol. 98, no. 3, pp. 351–360, 2006.

[37] M. Böttner, C. Suter-Cazzolara, A. Schober, and K. Unsicker, ”Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15 / macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues,” Cell and Tissue Research, vol. 297, no. 1, pp. 103–110, 1999.

[38] X.-Y. Xu, Y. Nie, F. F. Wang et al., ”Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation,” Journal of Biological Chemistry, vol. 289, no. 14, pp. 10084–10094, 2014.

[39] N. Nair and E. Gongora, ”Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy,” Journal of Circulating Biomarkers, vol. 7, 2018.

[40] Y. M. Zhou, M. J. Li, Y. L. Zhou, L. L. Ma, and X. Yi, ”Growth differentiation factor-15 (GDF-15), novel biomarker for asse-